Applied Radiology

Neuro MRI with Gadopiclenol

Presented by:
Pareen Mehta, MD

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

Effective Date: October 8, 2024  •  Expiration Date: October 31, 2027  •  Credits: 1.0

While GBCAs are essential to performing neuro MR imaging, guidance from the US Food and Drug Administration (FDA) and the American College of Radiology (ACR) includes the recommendation of limiting a patient's gadolinium exposure

One technique for reducing gadolinium exposure is to use a high-relaxivity gadolinium-based contrast agent (GBCA) that can be administered at a lower dose than a conventional GBCA without deteriorating image quality. Gadopiclenol, recently received FDA approval and is a high-relaxivity GBCA, designed to generate high-quality images at half the conventional dose of other GBCAs.

This educational program provides the clinical rationale for adopting the use of Gadopiclenol for neuro MRI and includes practice considerations for changing from one GBCA to another.

Through case study reviews, Pareen Mehta, MD, will share clinical insights into achieving optimal image quality using a lower administered gadolinium dose when performing neuro MRI.

Breast MRI with Gadopiclenol

Presented by:
Katja Pinker-Domenig, MD, PhD, EBBI, FISMRM, FSBI

Accredited by The Association for Medical Imaging Management (AHRA) for 1.0 Category A ARRT and CRA continuing education credits.

Effective Date: July 18, 2024  •  Expiration Date: July 31, 2027  •  Credits: 1.0

Dynamic contrast-enhanced breast MR imaging using gadolinium-based contrast agents (GBCAs) offers superior cancer detection to mammography and breast ultrasound due to the visualization of tumor neovascularity as a tumor-specific feature. Despite the clear advantages of breast MR imaging, it is currently recommended only for patients with a high lifetime risk of breast cancer, but recent data shows that there is also a benefit for women at a greater than average risk

While GBCAs are essential to performing breast MR imaging, guidance from the US Food and Drug Administration (FDA) and the American College of Radiology (ACR) includes the recommendation of limiting a patient's gadolinium exposure where possible. One technique for reducing gadolinium exposure is to use a high-relaxivity GBCA that can be administered at a lower dose than a conventional GBCA without deteriorating image quality. Gadopiclenol recently received FDA approval and is a high-relaxivity GBCA that decreases gadolinium exposure.

This educational program provides a clinical rationale for lowering the administered gadolinium dose when performing breast MRI on patients who may receive repeat MR contrasted exams throughout their lifetime for breast cancer screening. Through a review of case studies, Dr. Pinker-Domenig will provide insight on how to achieve optimal imaging while lowering the gadolinium dose with Gadopiclenol for breast MRI.